Inhibition of VRK1 suppresses proliferation and migration of vascular smooth muscle cells and intima hyperplasia after injury via mTORC1/β-catenin axis
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Characterized by abnormal proliferation and migration of vascular smooth muscle cells (VSMCs), neointima hyperplasia is a hallmark of vascular restenosis after percutaneous vascular interventions. Vaccinia-related kinase 1 (VRK1) is a stress adaptionassociated ser/thr protein kinase that can induce the proliferation of various types of cells. However, the role of VRK1 in the proliferation and migration of VSMCs and neointima hyperplasia after vascular injury remains unknown. We observed increased expression of VRK1 in VSMCs subjected to platelet-derived growth factor (PDGF)-BB by western blotting. Silencing VRK1 by shVrk1 reduced the number of Ki-67-positive VSMCs and attenuated the migration of VSMCs. Mechanistically, we found that relative expression levels of β-catenin and effectors of mTOR complex 1 (mTORC1) such as phospho (p)-mammalian target of rapamycin (mTOR), p-S6, and p-4EBP1 were decreased after silencing VRK1. Restoration of β-catenin expression by SKL2001 and re-activation of mTORC1 by Tuberous sclerosis 1 siRNA (siTsc1) both abolished shVrk1-mediated inhibitory effect on VSMC proliferation and migration. siTsc1 also rescued the reduced expression of β-catenin caused by VRK1 inhibition. Furthermore, mTORC1 re-activation failed to recover the attenuated proliferation and migration of VSMC resulting from shVrk1 after silencing β-catenin. We also found that the vascular expression of VRK1 was increased after injury. VRK1 inactivation in vivo inhibited vascular injury-induced neointima hyperplasia in a β-catenin-dependent manner. These results demonstrate that inhibition of VRK1 can suppress the proliferation and migration of VSMC and neointima hyperplasia after vascular injury via mTORC1/β-catenin pathway.
Abstract
Characterized by abnormal proliferation and migration of vascular smooth muscle cells (VSMCs), neointima hyperplasia is a hallmark of vascular restenosis after percutaneous vascular interventions. Vaccinia-related kinase 1 (VRK1) is a stress adaptionassociated ser/thr protein kinase that can induce the proliferation of various types of cells. However, the role of VRK1 in the proliferation and migration of VSMCs and neointima hyperplasia after vascular injury remains unknown. We observed increased expression of VRK1 in VSMCs subjected to platelet-derived growth factor (PDGF)-BB by western blotting. Silencing VRK1 by shVrk1 reduced the number of Ki-67-positive VSMCs and attenuated the migration of VSMCs. Mechanistically, we found that relative expression levels of β-catenin and effectors of mTOR complex 1 (mTORC1) such as phospho (p)-mammalian target of rapamycin (mTOR), p-S6, and p-4EBP1 were decreased after silencing VRK1. Restoration of β-catenin expression by SKL2001 and re-activation of mTORC1 by Tuberous sclerosis 1 siRNA (siTsc1) both abolished shVrk1-mediated inhibitory effect on VSMC proliferation and migration. siTsc1 also rescued the reduced expression of β-catenin caused by VRK1 inhibition. Furthermore, mTORC1 re-activation failed to recover the attenuated proliferation and migration of VSMC resulting from shVrk1 after silencing β-catenin. We also found that the vascular expression of VRK1 was increased after injury. VRK1 inactivation in vivo inhibited vascular injury-induced neointima hyperplasia in a β-catenin-dependent manner. These results demonstrate that inhibition of VRK1 can suppress the proliferation and migration of VSMC and neointima hyperplasia after vascular injury via mTORC1/β-catenin pathway.
참고문헌 (24)
- Thygesen K, "Fourth universal definition of myocardial infarction", Circulation, 138, pp.e618~ (2018)
- Byrne RA, "Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Gruntzig Lecture ESC 2014", Eur Heart J, 36, pp.3320~3331 (2015)
- Nicolais C, "Therapeutic options for in-stent restenosis", Curr Cardiol Rep, 20, pp.7~ (2018)
- Lacolley P, "Vascular smooth muscle cells and arterial stiffening : relevance in development, Aging, and Disease", Physiol Rev, 97, pp.1555~1617 (2017)
- Owens GK, "Molecular regulation of vascular smooth muscle cell differentiation in development and disease", Physiol Rev, 84, pp.767~801 (2004)
- Pendyala LK, "The first-generation drug-eluting stents and coronary endothelial dysfunction", JACC Cardiovasc Interv, 2, pp.1169~1177 (2009)
- Campillo-Marcos I, "The human VRK1 chromatin kinase in cancer biology", Cancer Lett, 503, pp.117~128 (2021)
- Valbuena A, "Roles of VRK1 as a new player in the control of biological processes required for cell division", Cell Signal, 23, pp.1267~1272 (2011)
- Vinograd-Byk H, "The spinal muscular atrophy with pontocerebellar hypoplasia gene VRK1 regulates neuronal migration through an amyloidbeta precursor protein-dependent mechanism", J Neurosci, 35, pp.936~942 (2015)
- Sun X, "NF2deficiency accelerates neointima hyperplasia following vascular injury via promoting YAP-TEAD1 interaction in vascular smooth muscle cells", Aging, 12, pp.9726~9744 (2020)
- An W, "Cezanne is a critical regulator of pathological arterial remodelling by targeting beta-catenin signalling", Cardiovasc Res (2021)
- Wang L, "VRK1 promotes proliferation, migration, and invasion of gastric carcinoma cells by activating beta-catenin", Neoplasma, 68, pp.1005~1014 (2021)
- Ha JM, "Platelet-derived growth factor regulates vascular smooth muscle phenotype via mammalian target of rapamycin complex 1", Biochem Biophys Res Commun, 464, pp.57~62 (2015)
- Fu Y, "SRSF1 and SRSF9RNA binding proteins promote Wnt signalling-mediated tumorigenesis by enhancing beta-catenin biosynthesis", EMBO Mol Med, 5, pp.737~750 (2013)
- Houssaini A, "Selective tuberous sclerosis complex 1 gene deletion in smooth muscle activates mammalian target of rapamycin signaling and induces pulmonary hypertension", Am J Respir Cell Mol Biol, 55, pp.352~367 (2016)
- Lin D, "Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of beta-catenin expression", Oncol Rep, 37, pp.895~902 (2017)
- Sun X, "Wild-type p53-induced phosphatase 1 promotes vascular smooth muscle cell proliferation and neointima hyperplasia after vascular injury via p-adenosine 5'-monophosphate-activated protein kinase", mammalian target of rapamycin complex 1 pathway, 2019, pp.37, 2256~2268
- Colmenero-Repiso A, "Identification of VRK1 as a new neuroblastoma tumor progression marker regulating cell proliferation", Cancers, 12, pp.3465~ (2020)
- Ren Z, "Downregulation of VRK1 reduces the expression of BANF1 and suppresses the proliferative and migratory activity of esophageal cancer cells", Oncol Lett, 20, pp.1163~1170 (2020)
- Tsaousi A, "Wnt4", betacatenin signaling induces VSMC proliferation and is associated with intimal thickening, 2011, pp.108, 427~436
- Hulin-Curtis S, "Targeting Wnt", beta-catenin activated cells with dominant-negative N-cadherin to reduce neointima formation, 2017, pp.5, 191~199
- Gao Z, "Mechanistic Insight into PPARgamma and Tregs in atherosclerotic immune inflammation", Front Pharmacol, 12, pp.750078~ (2021)
- Hall MN, "mTOR-what does it do?", Transplant Proc, 40, pp.S5~S8 (2008)
- Zhou P, "Ginsenoside Rb1ameliorates CKD-associated vascular calcification by inhibiting the Wnt", beta-catenin pathway, 2019, pp.23, 7088~7098